Contents

Preface ix

About the Authors xi

Chapter 1 Regulation of Preclinical Research 1
A. Introduction 1
B. Animal Use in Biomedical Research and Testing 2
1. The Basic Regulatory Scheme—the Animal Welfare Act and Regulations 2
3. Memorandum of Understanding Among APHIS, FDA, and the NIH 13
4. NIH Considerations 14
5. FDA Considerations and Good Laboratory Practices 18
6. CDC Considerations 19
7. State Law 19
8. Conclusion 19
C. Other Regulatory Schemes Applicable to Preclinical Research—Protection of the Environment and Public Health 20
1. Introduction 20
2. EPA Jurisdiction and RCRA 20
3. Applying Environmental Law to Academic Research Facilities 22
4. IACUC Responsibility 23
5. The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 and Select Agents and Toxins 23

D. Other Regulatory Schemes Applicable to Preclinical Research—Occupational Safety and Health Considerations and the Protection of Individuals Conducting Preclinical Research 26
1. Introduction 26
2. OSHA Regulation, Standards, and Resources 27
3. Selected Resource Tools—Chemicals and Biohazards 28
4. Radioactive Materials in the Research Setting 29
E. Conclusion 29

Chapter 2 Federal Regulation of Clinical Research 31

A. Background 32
1. The Role of Clinical Research 32
2. Government Entities That Regulate Clinical Research 33

B. The Roles and Responsibilities of the Parties 38
1. Subject 38
2. Sponsor 38
3. Principal Investigator 39
4. Contract Research Organization 39
5. Monitor 40
6. Institutional Review Board 40
7. Data Monitoring Committee 40
8. Institutional Biosafety Committee 41

C. Premarket Clinical Trial Process 41
1. Drug Trials 41
2. Device Trials 43
3. Prior to Start of Clinical Trial 43
4. Conducting the Trial 52
5. After the Trial 57

D. Enforcement 60
1. FDA Inspections 60
2. Form 483 Observations 61
3. Warning and Untitled Letters 61
4. Administrative Consequences 62
5. Civil and Criminal Liability 64
E. Other Issues 64
   1. Postmarket Trials 64
   2. Sites and Trials in Foreign Countries 66
   3. Expanded Access 68

Chapter 3 Approval of Biotechnology Products for Human Use 71
A. Introduction 72
   1. Overview of the FDA Approval Process 72
B. Standard Pathways to Market 77
   1. Drugs: The Traditional New Drug Application 77
   2. Drugs: The Faster 505(b)(2) Application 84
   3. Biological Products 85
   4. Medical Devices 91
   5. Combination Products 93
C. Expedited Pathways to Market 96
   1. Fast Track 96
   2. Breakthrough Therapies 97
   3. Accelerated Approval 99
   4. Priority Review 99
   5. Orphan Drug Designation 100
   6. Humanitarian Use Device 102
D. Future Pathways to Market 102

Chapter 4 Federal and State Regulation After Approval 105
A. Regulatory Authorities 106
   1. Food and Drug Administration 106
   2. Office of Inspector General, Department of Health and Human Services 107
   3. Department of Justice Civil Division 108
   5. Securities and Exchange Commission 109
B. Postapproval Responsibilities 109
   1. Current Good Manufacturing Practice 109
   2. Postapproval Reporting 112
   3. Import and Export Requirements 117
   4. Regulation of Advertising and Labeling 120
C. Withdrawal of FDA Approval 130
D. False Claims Act 131
2. The Serono Laboratories Serostim Settlement (2005) 132
3. The Bristol-Myers Squibb Abilify Settlement (2007) 133
8. The Amgen Aranesp Settlement (2012) 137
10. The J&J Risperdal Settlement (2013) 139
11. The Genzyme Seprafilm Settlement (2013) 140
12. Endo Pharmaceuticals (2014) 140
E. Anti-Kickback Statute and Other Illegal Remuneration 141
F. The Physicians Payments Sunshine Act 142

Index 143